Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2006

View Archived Issues

2005 achievements at VioQuest

MKC-733 demonstrates potential in constipation

Inhaled hypertonic saline benefits cystic fibrosis patients

p53 tumor suppressor harbors antioxidant function

NEPP compounds provide neuroprotection via modulation of Keap1/Nrf2 to activate HO-1

New GPR109b agonists as antilipolytic agents

Novel nonsteroidal selective 5alpha-reductase type 2 inhibitor presented

Novartis makes steady progress in Q4

Metaglidasen as effective as thiazolidinediones for glycemic control

Xience V stent system moves closer to European approval

Orphan drug designation for ACR-16 for Huntington's disease

Guidant settles on merger with Boston Scientific

Kosan studies oral Hsp90 inhibitor KOS-1022 in phase I trial

Transgene receives funding for HCV therapeutic vaccine program

Manufacturing milestone in RiVax development

Updated labeling approved for Elidel and Protopic

Orphan drug status for Myodur in Duchenne and Becker muscular dystrophies

Targeted Genetics restructures

Phase I study for EM-1421 in unresponsive tumors

Dainippon Sumitomo and Aska end agreement

NeuroSearch to continue development of tesofensine

European approval for Kiovig

New IP receptor antagonists from Roche show analgesic potential

Recent AstraZeneca patent reports novel GABA-B receptor modulators

Recent patents report novel agents for obesity and lipoprotein disorders

Novel tachykinin NK1 antagonists disclosed in recent Merck & Co. patent

Ono patents novel compounds for transplant rejection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...